pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Jury deliberates conflicting accounts in David Sabatini misconduct trial at Whitehead Institute

Oct 16, 2026·read at STAT ↗Negative

A Boston jury is hearing a civil case that pits two very different narratives about the conduct of renowned molecular biologist David Sabatini. The three‑week trial has focused on accusations that Sabatini used his position to coerce a younger colleague into a sexual relationship and fostered a hostile lab environment at the Whitehead Institute.

The accused scientist and his supporters argue that the allegations stem from a personal vendetta by a former romantic partner, claiming the claims are part of a broader #MeToo backlash. Testimony and text messages presented in court have been sharply contested, leaving jurors to weigh the credibility of each side.

Beyond the individual dispute, the case highlights ongoing challenges in academic research settings, where power imbalances can blur professional boundaries. Observers note that the outcome may influence how institutions address misconduct allegations and enforce workplace standards in high‑profile scientific labs.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Coerced sex or a jealous ex? Jury weighs dueling accounts of star scientist David Sabatini’s downfall”

read at STAT ↗
437 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
topics
OncologyPeptide TherapeuticRare DiseaseVaccine

related stories

  • 20h agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Aug 14Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersBioPharma Dive
  • Jul 23FDA panel confronting peptide controversySTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 11MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumorsonclive